Allogene Therapeutics, Inc. has reported that on April 14, 2026, it entered into an underwriting agreement to sell 87.5 million shares of its common stock at $2.00 per share, expecting to raise approximately $175 million before expenses. The offering is set to close on April 16, 2026, and will help fund various corporate purposes including clinical trials and research.